{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:25:36Z","timestamp":1776705936532,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bulcan.2021.12.013","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:51:38Z","timestamp":1643590298000},"page":"S123-S131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S","title":["Prise en charge du syndrome de neurotoxicit\u00e9 associ\u00e9e au traitement par cellules CAR-T chez l\u2019adulte et l\u2019enfant\u00a0: recommandations de la SFGM-TC"],"prefix":"10.1016","volume":"110","author":[{"given":"Muriel","family":"Picard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Sterin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Courbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne- Sophie","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciane","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pochon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Tudesq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bulcan.2021.12.013_bib0170","first-page":"35","article-title":"CAR T-cells: a John von Neumann legacy?","volume":"66","author":"Quesnel B:","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.bulcan.2021.12.013_bib0175","first-page":"559","article-title":"Chimeric antigen receptor T-cell therapy for ALL","volume":"2014","author":"Maude","year":"2014","journal-title":"ASH Education Program Book"},{"issue":"1","key":"10.1016\/j.bulcan.2021.12.013_bib0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2021.12.013_bib0185","first-page":"159","article-title":"Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials","volume":"68","author":"Yassine","year":"2020","journal-title":"Curr Res Transl Med"},{"issue":"5","key":"10.1016\/j.bulcan.2021.12.013_bib0190","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/CCO.0000000000000667","article-title":"Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"32","author":"Beauvais","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2021.12.013_bib0195","first-page":"93","article-title":"Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives","volume":"65","author":"Gauthier","year":"2017","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2021.12.013_bib0200","first-page":"43","article-title":"Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma","volume":"66","author":"Ghobadi A:","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2021.12.013_bib0205","first-page":"37","article-title":"Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia","volume":"66","author":"Prommersberger","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.bulcan.2021.12.013_bib0210","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fimmu.2020.00482","article-title":"Point-Of-Care CAR T-Cell Production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial","volume":"11","author":"Castella","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.12.013_bib0215","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: a Multicenter Trial of ARI-0001\u00a0Cell Therapy in Patients with CD19(+) Relapsed\/Refractory Malignancies","volume":"29","author":"Ortiz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2021.12.013_bib0220","article-title":"Management of CAR T cell-related encephalopathy syndrome in adult and pediatric patients: Recommendations of the French Society of Bone Marrow transplantationand cellular Therapy (SFGM-TC)","author":"Cornillon","year":"2019","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2021.12.013_bib0225","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: A phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.12.013_bib0230","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2\u00a0EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2021.12.013_bib0235","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19\u00a0chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2021.12.013_bib0240","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","article-title":"Chimeric antigen receptor T Cell-related neurotoxicity: mechanisms, clinical presentation, and approach to treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"8","key":"10.1016\/j.bulcan.2021.12.013_bib0245","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-Cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.bulcan.2021.12.013_bib0250","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-Cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.bulcan.2021.12.013_bib0255","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1\u00a0blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2021.12.013_bib0260","article-title":"Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity","author":"Pensato","year":"2021","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.12.013_bib0265","first-page":"50","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2021.12.013_bib0270","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8.","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2021.12.013_bib0275","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.12.013_bib0280","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bulcan.2021.12.013_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19\u00a0CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.12.013_bib0290","first-page":"17","article-title":"Treatment with anti CD19\u00a0chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia","volume":"68","author":"Danylesko","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"224","key":"10.1016\/j.bulcan.2021.12.013_bib0295","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.bulcan.2021.12.013_bib0300","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2021.12.013_bib0305","article-title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT","author":"Hayden","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"4","key":"10.1016\/j.bulcan.2021.12.013_bib0310","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2021.12.013_bib0315","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41416-018-0342-0","article-title":"Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma","volume":"120","author":"Wang","year":"2019","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2021.12.013_bib0320","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2021.12.013_bib0325","first-page":"103285","article-title":"The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity","volume":"69","author":"Aqel","year":"2021","journal-title":"Curr Res Transl Med"},{"issue":"10","key":"10.1016\/j.bulcan.2021.12.013_bib0165","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122000133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122000133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:47Z","timestamp":1757792207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122000133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0007455122000133"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.12.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge du syndrome de neurotoxicit\u00e9 associ\u00e9e au traitement par cellules CAR-T chez l\u2019adulte et l\u2019enfant\u00a0: recommandations de la SFGM-TC","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}